

This notice in TED website:

NOT RELEVANT

United Kingdom-Edinburgh: Pharmaceutical products
2017/S 039-070527

Contract notice

Supplies

Directive 2014/24/EU

Section I: Contracting authority

I.1) Name and addresses

The Common Services Agency (more commonly known as NHS National Services Scotland) ('the Authority')
Gyle Square (NSS Head Office), 1 South Gyle Crescent
Edinburgh
EH12 9EB
United Kingdom
Contact person: Hazel Johnstone
Telephone: **GRO-C**
E-mail: [hazel.johnstone@](mailto:hazel.johnstone@nhs.uk) **GRO-C**
NUTS code: UKM

Internet address(es):

Main address: <http://www.nhsscotlandprocurement.scot.nhs.uk/>

Address of the buyer profile: http://www.publiccontractsscotland.gov.uk/search/Search_AuthProfile.aspx?ID=AA11883

I.2) Joint procurement

The contract is awarded by a central purchasing body

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at: <https://www.publictendersscotland.publiccontractsscotland.gov.uk/web/login.html>
Additional information can be obtained from the abovementioned address
Tenders or requests to participate must be submitted electronically via: <https://www.publictendersscotland.publiccontractsscotland.gov.uk/web/login.html>

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title:

Supply of Intravenous Immunoglobulin (IVIgG) and Subcutaneous Immunoglobulin (IgG).
Reference number: NP32617

II.1.2) Main CPV code

33600000

II.1.3) **Type of contract**

Supplies

II.1.4) **Short description:**

This Framework Agreement is for the supply of Intravenous Immunoglobulin (IVIgG) and Subcutaneous Immunoglobulin (IgG).

The Goods have been split into four (4) categories, each of which is identified as a 'Lot'.

The Lots are as follows:

Lot 1 — Human Normal Intravenous Immunoglobulin 5 %

Lot 2 — Human Normal Intravenous Immunoglobulin 10 %

Lot 3 — Human Normal Intravenous Immunoglobulin for Subcutaneous Use

Lot 4 — Subcutaneous Immunoglobulin with Hyaluronidase

All deliveries under the framework agreement will be to one central location, namely 'The Scottish National Blood Transfusion Service' (SNBTS), Edinburgh.

II.1.5) **Estimated total value**

Value excluding VAT: 78 000 000.00 GBP

II.1.6) **Information about lots**

This contract is divided into lots: yes

Tenders may be submitted for all lots

II.2) **Description**

II.2.1) **Title:**

Supply of Human Normal Intravenous Immunoglobulin 5 %

Lot No: 1

II.2.2) **Additional CPV code(s)**

33141520

33651520

II.2.3) **Place of performance**

NUTS code: UKM

Main site or place of performance:

Scottish National Blood Transfusion Service (SNBTS), Edinburgh.

II.2.4) **Description of the procurement:**

Supply of Human Normal Intravenous Immunoglobulin 5 %, across various vial sizes including current Primary Immune Deficiencies (PID) usage.

This lot will be awarded as a Ranked Multi Supplier Framework. It is envisaged that a maximum of six (6) suppliers will be awarded to this lot.

II.2.5) **Award criteria**

Criteria below

Quality criterion - Name: Range of Vial Sizes / Weighting: 10

Quality criterion - Name: Storage Conditions / Weighting: 5

Price - Weighting: 85

II.2.6) **Estimated value**

Value excluding VAT: 4 450 000.00 GBP

II.2.7) **Duration of the contract, framework agreement or dynamic purchasing system**

Duration in months: 24

This contract is subject to renewal: yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the twenty four (24) month duration of the Framework Agreement by two (2) periods of up to twelve (12) months each by giving a minimum of three (3) months written notice of such extension.

II.2.10) Information about variants

Variants will be accepted: no

II.2.11) Information about options

Options: no

II.2.12) Information about electronic catalogues

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) Additional information

II.2) Description

II.2.1) Title:

Supply of Human Normal Intravenous Immunoglobulin 10 %

Lot No: 2

II.2.2) Additional CPV code(s)

33141520

33651520

II.2.3) Place of performance

NUTS code: UKM

Main site or place of performance:

Scottish National Blood Transfusion Service (SNBTS), Edinburgh.

II.2.4) Description of the procurement:

Supply of Human Normal Intravenous Immunoglobulin 10 %, across various vial sizes including current Primary Immune Deficiencies (PID) usage.

This lot will be awarded as a Ranked Multi Supplier Framework. It is envisaged that a maximum of six (6) suppliers will be awarded to this lot.

II.2.5) Award criteria

Criteria below

Quality criterion - Name: Range of Vial Sizes / Weighting: 10

Quality criterion - Name: Storage Conditions / Weighting: 5

Price - Weighting: 85

II.2.6) Estimated value

Value excluding VAT: 60 000 000.00 GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the twenty four (24) month duration of the Framework Agreement by two (2) periods of up to twelve (12) months each by giving a minimum of three (3) months written notice of such extension.

II.2.10) **Information about variants**

Variants will be accepted: no

II.2.11) **Information about options**

Options: no

II.2.12) **Information about electronic catalogues**

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

II.2) **Description**

II.2.1) **Title:**

Supply of Human Normal Intravenous Immunoglobulin for subcutaneous use

Lot No: 3

II.2.2) **Additional CPV code(s)**

33141520

33651520

II.2.3) **Place of performance**

NUTS code: UKM

Main site or place of performance:

Scottish National Blood Transfusion Service (SNBTS), Edinburgh.

II.2.4) **Description of the procurement:**

Supply of Human Normal Intravenous Immunoglobulin for subcutaneous use across various vial sizes including current Primary Immune Deficiencies (PID) usage.

This lot will be awarded as a Ranked Multi Supplier Framework. It is envisaged that a maximum of six (6) suppliers will be awarded to this lot.

II.2.5) **Award criteria**

Criteria below

Quality criterion - Name: Range of Vial Sizes / Weighting: 10

Quality criterion - Name: Storage Conditions / Weighting: 5

Price - Weighting: 85

II.2.6) **Estimated value**

Value excluding VAT: 13 550 000.00 GBP

II.2.7) **Duration of the contract, framework agreement or dynamic purchasing system**

Duration in months: 24

This contract is subject to renewal: yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the twenty four (24) month duration of the Framework

Agreement by two (2) periods of up to twelve (12) months each by giving a minimum of three (3) months written notice of such extension.

II.2.10) **Information about variants**

Variants will be accepted: no

II.2.11) **Information about options**

Options: no

II.2.12) **Information about electronic catalogues**

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

II.2) **Description**

II.2.1) **Title:**

Supply of Subcutaneous Immunoglobulin with Hyaluronidase
Lot No: 4

II.2.2) **Additional CPV code(s)**

33141520
33651520

II.2.3) **Place of performance**

NUTS code: UKM
Main site or place of performance:
Scottish National Blood Transfusion Service (SNBTS), Edinburgh.

II.2.4) **Description of the procurement:**

Supply of Subcutaneous Immunoglobulin with Hyaluronidase. The Authority intends awarding all presentations within this Lot to a single supplier.

II.2.5) **Award criteria**

Criteria below
Quality criterion - Name: Range of Vial Sizes / Weighting: 10
Quality criterion - Name: Storage Conditions / Weighting: 5
Price - Weighting: 85

II.2.6) **Estimated value**

II.2.7) **Duration of the contract, framework agreement or dynamic purchasing system**

Duration in months: 24
This contract is subject to renewal: yes
Description of renewals:
The Authority is entitled at its sole discretion to extend the twenty four (24) month duration of the Framework Agreement by two (2) periods of up to twelve (12) months each by giving a minimum of three (3) months written notice of such extension.

II.2.10) **Information about variants**

Variants will be accepted: no

II.2.11) **Information about options**

Options: no

II.2.12) **Information about electronic catalogues**

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

Section III: Legal, economic, financial and technical information

III.1) **Conditions for participation**

III.1.1) Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers

List and brief description of conditions:

Economic operators may be excluded from this competition if they are in breach of any of the situation referred to in regulation 58 of the Public Contracts (Scotland) Regulations 2015.

III.1.2) Economic and financial standing

III.1.3) Technical and professional ability

List and brief description of selection criteria:

(a) Potential Framework Participants must be able to demonstrate the existence of a valid and current UK Marketing Authorisation or EMA Marketing Authorisation that has been approved by approved by the MHRA for all tendered Medicines at the date of submission of the tender.

(b) Potential Framework Participants and any sub-contractor(s) must possess valid certification of BS EN ISO 9001 or equivalent.

Minimum level(s) of standards possibly required:

(a) Confirmation of existence of a valid and current UK Marketing Authorisation or EMA Marketing Authorisation that has been approved by the MHRA for all tendered Medicines at the date of submission of the tender should be included in the Qualification Envelope of the ITT under the Technical and Professional ability: Quality Control.

(b) Confirmation of the existence of valid certification of BS EN ISO 9001 or equivalent. Confirmation of such certification should be included in the Qualification Envelope of the ITT under the Quality Assurance Schemes.

III.1.5) Information about reserved contracts

III.2) Conditions related to the contract

III.2.2) Contract performance conditions:

III.2.3) Information about staff responsible for the performance of the contract

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.3) Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement

Framework agreement with several operators

Envisaged maximum number of participants to the framework agreement: 6

IV.1.4) Information about reduction of the number of solutions or tenders during negotiation or dialogue

IV.1.6) Information about electronic auction

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: yes

IV.2) Administrative information

IV.2.1) Previous publication concerning this procedure

IV.2.2) Time limit for receipt of tenders or requests to participate

Date: 27/03/2017

Local time: 12:00

IV.2.3) Estimated date of dispatch of invitations to tender or to participate to selected candidates

IV.2.4) Languages in which tenders or requests to participate may be submitted:

English

IV.2.6) **Minimum time frame during which the tenderer must maintain the tender**

Duration in months: 3 (from the date stated for receipt of tender)

IV.2.7) **Conditions for opening of tenders**

Date: 27/03/2017

Local time: 12:00

Section VI: Complementary information

VI.1) **Information about recurrence**

This is a recurrent procurement: no

VI.2) **Information about electronic workflows**

Electronic ordering will be used

Electronic invoicing will be accepted

Electronic payment will be used

VI.3) **Additional information:**

The estimated values referred to in this notice cover the initial twenty-four (24) months duration of the Framework Agreement and the full twenty-four (24) months extension options.

The buyer is using PCS-Tender to conduct this ITT exercise. The Project code is 7531. For more information see: <http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2343>

The Contracting Authority does not intend to include a sub-contract clause as part of community benefits (as per Section 25 of the Procurement Reform (Scotland) Act 2014) in this contract for the following reason:

It is not envisaged that sub-contractors will be utilised in delivery of this framework agreement.

The Contracting Authority does not intend to include any community benefit requirements in this contract for the following reason:

No Community Benefits will be deliverable through the award of this framework agreement.

(SC Ref:479229).

VI.4) **Procedures for review**

VI.4.1) **Review body**

The Common Services Agency (more commonly known as NHS National Services Scotland) ('the Authority')

Gyle Square (NSS Head Office), 1 South Gyle Crescent

Edinburgh

EH12 9EB

United Kingdom

Telephone: +44 1698794410

Internet address:<http://www.nhsscotlandprocurement.scot.nhs.uk/>

VI.4.2) **Body responsible for mediation procedures**

VI.4.3) **Review procedure**

Precise information on deadline(s) for review procedures:

The Authority will notify economic operators who submitted a tender or (where no deselection notification has previously been made) applied to be selected to tender, of its decision to award the framework agreement which notification will contain among other information, a summary of the reasons why the economic operator was unsuccessful. The notification will incorporate a 'standstill period' of a minimum of 10 clear calendar days (or a minimum of 15 if the communication method used is not electronic) between the date on which the Authority despatches the notice(s) and the date on which the Authority proposes to conclude the relevant framework agreement. The bringing of court proceedings against the Authority during the standstill period will

automatically continue the prohibition on entering into the framework agreement until the court proceedings are determined, discontinued or disposed of, or the court, by interim order, brings to an end the prohibition. The remedies that may be awarded by the courts before the framework agreement has been entered into include the setting aside of the decision to award the framework agreement to the winning tenderer(s). The bringing of court proceedings against the Authority after the framework agreement has been entered into will not affect the framework agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise the remedies that may be awarded by the courts where the framework agreement has been entered into are limited to the award of damages.

VI.4.4) **Service from which information about the review procedure may be obtained**

VI.5) **Date of dispatch of this notice:**

23/02/2017